Integril is administered as an intravenous bolus followed by a continuous intravenous infusion, typically in a hospital setting under close medical supervision.

Eptifibatide is a reversible glycoprotein IIb/IIIa receptor antagonist. It binds to the platelet glycoprotein IIb/IIIa receptor, preventing the binding of fibrinogen, von Willebrand factor, and other adhesive ligands. This inhibits the final common pathway of platelet aggregation, thereby preventing the formation of blood clots.

• •Active pathological bleeding or a history of bleeding diathesis within the preceding 30 days.
• •History of stroke within 30 days or any hemorrhagic stroke.
• •Major surgery within the preceding 6 weeks.
• •Severe uncontrolled hypertension (systolic blood pressure >200 mm Hg or diastolic blood pressure >110 mm Hg) refractory to antihypertensive therapy.
• •History of thrombocytopenia following previous administration of a glycoprotein IIb/IIIa inhibitor.
• •Dependence on renal dialysis.

Store refrigerated at 2°C to 8°C (36°F to 46°F). Protect from light. Do not freeze. Discard any unused portion.

Overdose of Integril can lead to increased bleeding complications. Management involves discontinuing Integril and other antithrombotic agents, careful monitoring, and supportive therapy, which may include transfusion of blood products (e.g., platelets) if severe bleeding occurs.

Pregnancy Category B. Studies in animals have shown no evidence of fetal harm, but there are no adequate and well-controlled studies in pregnant women. Use only if clearly needed. It is not known whether eptifibatide is excreted in human milk; caution should be exercised when administered to a nursing mother.